FDA Pilots Risk-Based Model for Prioritizing Plant Inspections

No longer able to inspect drug manufacturing establishments as often as it would like, FDA, as part of its cGMPs for the 21st Century, will pilot a risk-based inspection model for prioritizing manufacturers for routine inspection. Those efforts are outlined in this white paper.